In the realm of breast cancer treatments, a preclinical study suggests that overcoming resistance to trastuzumab in HER2/Neu+ breast cancer can be achieved by combining CD47 blockade with trastuzumab (33). This evidence concerns the gene ERBB2 and breast carcinoma.